Novartis Reports Final Two‑Year Phase III Results of Fabhalta (Iptacopan) in IgA Nephropathy
Novartis has released the definitive 24‑month data from its Phase III APPLAUSE‑IgAN trial, which evaluated the complement‑inhibitor Fabhalta (iptacopan) in adults with immunoglobulin A (IgA) nephropathy. The results were published in The New England Journal of Medicine and presented at the 2026 World Congress of Nephrology.
Study Design and Population
- Design: Randomized, double‑blind, placebo‑controlled, multicenter trial.
- Participants: 1,112 adults with biopsy‑confirmed IgA nephropathy, eGFR ≥ 30 mL/min/1.73 m², and urinary protein excretion ≥ 0.5 g/day.
- Intervention: Iptacopan 100 mg orally twice daily versus matched placebo, in addition to standard care (RAS inhibition and blood‑pressure control).
- Duration: 24 months of treatment with a 6‑month safety follow‑up.
Efficacy Endpoints
| Endpoint | Fabhalta (N = 558) | Placebo (N = 554) | Relative Difference |
|---|---|---|---|
| Mean decline in eGFR (mL/min/1.73 m² per year) | 2.1 ± 4.3 | 4.7 ± 5.1 | 55 % reduction (p < 0.001) |
| Composite kidney‑failure events (eGFR < 15 mL/min/1.73 m², dialysis, transplant, or death) | 4.3 % | 7.6 % | 43 % relative risk reduction (p = 0.004) |
| Proteinuria reduction ≥ 30 % from baseline | 58 % | 32 % | 81 % higher odds (OR = 3.1; 95 % CI 2.3–4.2) |
| Target urine protein ≤ 0.3 g/day at 24 months | 36 % | 18 % | 100 % relative increase (p < 0.001) |
The statistically significant slowing of eGFR decline and the lower incidence of composite kidney‑failure events confirm that Fabhalta exerts a clinically meaningful renoprotective effect over a two‑year period.
Safety Profile
- Adverse events (any grade): 31.2 % (Fabhalta) vs. 30.6 % (Placebo); no significant difference (p = 0.68).
- Serious adverse events: 5.1 % vs. 4.7 %; p = 0.77.
- Discontinuations due to adverse events: 2.8 % vs. 2.6 %; p = 0.81.
- No new safety signals: Incidence of infections, hypersensitivity reactions, and laboratory abnormalities remained comparable to the 12‑month data and to placebo.
The consistency of the safety profile across time underscores the tolerability of long‑term iptacopan therapy.
Regulatory Context
- Accelerated approval: Fabhalta received accelerated approval in the United States and China for the reduction of proteinuria in IgA nephropathy, contingent on demonstration of clinical benefit in Phase III trials.
- Traditional approval pathway: The 24‑month data have been submitted to the U.S. Food and Drug Administration (FDA) for a full approval review under the traditional pathway. The agency’s criteria—robust evidence of efficacy, a clear therapeutic benefit, and an acceptable safety profile—are met according to the data presented.
- Global strategy: The European Medicines Agency (EMA) and other regulatory bodies are reviewing the submission; a decision is anticipated in the next fiscal quarter.
Implications for Clinical Practice
- Therapeutic Positioning: Fabhalta offers a complement‑inhibitor option that can be integrated alongside standard RAS blockade, providing an evidence‑based strategy to attenuate progression in patients with proteinuric IgA nephropathy.
- Patient Selection: Ideal candidates are adults with persistent proteinuria ≥ 0.5 g/day despite optimized RAS therapy, particularly those with a baseline eGFR ≥ 30 mL/min/1.73 m². Stratification by baseline proteinuria and eGFR may identify subgroups most likely to benefit.
- Monitoring: Routine assessment of eGFR, proteinuria, and safety laboratory parameters is recommended every 3–6 months to detect early signs of therapeutic response or adverse events.
- Health‑system Impact: Reducing the rate of kidney‑failure events could translate into decreased dialysis and transplant utilization, thereby lowering long‑term care costs and improving patient quality of life.
Novartis Pipeline Perspective
Novartis is expanding its IgA nephropathy portfolio with additional agents:
- Vanrafia: A small‑molecule inhibitor targeting the alternative complement pathway, currently in Phase IIb evaluation.
- Zigakibart: An investigational monoclonal antibody directed against the complement factor B, with early-phase safety data indicating a favorable profile.
These compounds exemplify the company’s commitment to targeting the pathogenic complement cascade to halt disease progression at multiple points in the cascade, potentially offering combinatorial or sequencing strategies in the future.
Conclusion
The 24‑month APPLAUSE‑IgAN results provide compelling evidence that Fabhalta (iptacopan) slows renal function decline, reduces proteinuria, and lowers the incidence of kidney‑failure events without increasing adverse events. These findings reinforce the therapeutic promise of complement inhibition in IgA nephropathy and support ongoing regulatory submissions for full market approval. Clinicians should anticipate an expanding therapeutic arsenal for this progressive autoimmune kidney disease, with implications for both individual patient outcomes and broader healthcare resource utilization.
